Regulatory Expert Appointed to Lead West Coast US Client Engagement for G&L Healthcare Advisors

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MADISON, NJ / ACCESSWIRE / June 3, 2024 / G&L Healthcare Advisors is delighted to announce that Richard Edmunds, a 25-year veteran in regulatory affairs, will take on a new client engagement role and lead our U.S. West Coast business expansion, based out of G&L’s San Diego, California, office.

Richard Edmunds, G&L Healthcare Advisors
Richard Edmunds, G&L Healthcare Advisors

Bringing decades of regulatory and clinical development experience, Richard will partner with both biotech and pharma customers to expedite drug development and product launch. Richard has a strong track record of helping over 50 companies secure regulatory approval.

Richard brings a unique and compelling combination of technical expertise and business acumen that helps our clients achieve their goals, whatever their stage of development.

He has assisted clients in initiating proof-of-concept studies and securing funding; reaching Ph1/2 clinical trial inflection point; gearing up for product approval and launch; increasing revenue through global expansion; or implementing cost-effective models for post-approval activities, technology solutions, and more.

Commenting on Richard’s appointment, G&L’s COO, Dave Yungvirt, said:

“We are excited that Richard has agreed to help take G&L to the next level, as part of our continued growth, serving our West Coast clients to ultimately meet patient needs.”

Schedule your appointment with Richard today: https://calendly.com/redmunds-e3vm/g-l-health-introduction

About G&L Healthcare Advisors

Built upon the foundation of decades of delivering industry-leading regulatory and quality services, G&L Healthcare Advisors (G&L) is rapidly evolving into a trusted and innovative biopharmaceutical solutions provider.

Harnessing both global expertise and cutting-edge technology, G&L is expertly positioned to support the pharmaceutical, biopharmaceutical and biotechnology industry as it undergoes a scientific renaissance.

We aim to provide a single, unified source of best-in-class solutions across the entire product lifecycle, spanning business model organization, drug development, regulatory and quality, commercial launch, and market access.

Contact Information

Jonathan Walmsley
Communications Manager
jwalmsley@gandlhealth.com

SOURCE: G&L Healthcare Advisors

View the original press release on newswire.com.

Staff

Recent Posts

Waystar Appoints Aashima Gupta and Michael Roman to Board of Directors

New directors bring deep expertise in AI innovation, healthcare, and enterprise growth LEHI, Utah and…

5 hours ago

Occupational Health Market to Reach USD 8,453.96 million By 2032, Growing At An 6.50% CAGR – Credence Research

PUNE, India, June 16, 2025 /PRNewswire/ -- The global Occupational Health Market was valued at USD…

5 hours ago

AdventHealth Tampa first in region to perform colorectal surgery using da Vinci SP robot

TAMPA, Fla., June 16, 2025 /PRNewswire/ -- AdventHealth Tampa is now the first hospital in…

5 hours ago

AARP Services Announces New AARP Member Benefits Launching This Summer

WASHINGTON, June 16, 2025 /PRNewswire/ -- Today, it has been announced that AARP members have the…

5 hours ago

C-Path’s New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects

BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ -- The Innovative Health Initiative (IHI) and Critical…

5 hours ago

Introducing Archy Intelligence™: Your Newest (AI) Team Members

Archy unveils the future of dental software—where AI works like a teammate, not just a…

5 hours ago